Corporate GovernanceApr 30, 2026, 05:21 PM
TCRT Amends 10-K to Add Part III Info; Details CEO, Board Changes
AI Summary
Alaunos Therapeutics, Inc. (TCRT) filed an amended 10-K to include Part III information, previously omitted, covering corporate governance and executive compensation. The amendment details the appointment of Holger Weis as CEO in July 2025 with an annual base salary of $275,000 and an option to purchase 130,000 shares. It also outlines changes to the Board of Directors, including the appointment of Michael A. Jerman and the resignations of Dale Curtis Hogue and Dr. Robert Hofmeister, along with executive compensation for 2025 and 2024.
Key Highlights
- TCRT amended its 10-K to include Part III information on corporate governance and executive compensation.
- Holger Weis appointed CEO on July 2, 2025, with an annual base salary of $275,000.
- Mr. Weis was granted an option to purchase 130,000 shares at $5.06 per share.
- Michael A. Jerman appointed director July 15, 2025; Dale Curtis Hogue, Jr. and Dr. Robert Hofmeister resigned.
- Ferdinand Groenewald's 2025 total compensation was $216,988.
- Dale Curtis Hogue, Jr.'s 2025 total compensation was $143,492.
- The Compensation Committee engaged Pearl Meyer and Partners, LLC in June 2025 as its independent consultant.